Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. JACC. Heart failure Abraham, W. T., Psotka, M. A., Fiuzat, M. n., Filippatos, G. n., Lindenfeld, J. n., Mehran, R. n., Ambardekar, A. V., Carson, P. E., Jacob, R. n., Januzzi, J. L., Konstam, M. A., Krucoff, M. W., Lewis, E. F., Piccini, J. P., Solomon, S. D., Stockbridge, N. n., Teerlink, J. R., Unger, E. F., Zeitler, E. P., Anker, S. D., O'Connor, C. M. 2020

Abstract

The Heart Failure Academic Research Consortium is a partnership between the Heart Failure Collaboratory (HFC) and Academic Research Consortium (ARC), comprised of leading heart failure (HF) academic research investigators, patients, United States (US) Food and Drug Administration representatives, and industry members from the US and Europe. A series of meetings were convened to establish definitions and key concepts for the evaluation of HF therapies including optimal medical and device background therapy, clinical trial design elements and statistical concepts, and study endpoints. This manuscript summarizes the expert panel discussions as consensus recommendations focused on populations and endpoint definitions; it is not exhaustive or restrictive, but designed to stimulate HF clinical trial innovation.

View details for DOI 10.1016/j.jchf.2020.10.002

View details for PubMedID 33199251